For investors looking to join solid fundamental growth with well-timed technical entry points, a multi-factor screening method can be an effective instrument. By selecting for stocks that show strong earnings momentum, good technical condition, and a price pattern that is coming together, the aim is to find companies that are not only expanding quickly but are also set for a possible price move upward. This process brings together the ideas of high-growth momentum investing, which centers on speeding up earnings and sales, with technical study that finds the best entry points. One stock that recently appeared from such a screen is Arcutis Biotherapeutics Inc (NASDAQ:ARQT), a clinical-stage biopharmaceutical company working on skin diseases.
High Growth Momentum Fundamentals
The center of the high-growth momentum plan is finding companies with speeding business results, and Arcutis makes a strong case from the given numbers. The company's High Growth Momentum (HGM) Rating of 7 shows force across several important growth and momentum measures.
- Very High Earnings Growth: The newest quarter shows a very high year-over-year EPS growth of 244.4%. This comes after a pattern of big speeding up, with the earlier quarters growing 118.2%, 69.0%, and 37.5% in turn. This clear line of speeding quarterly earnings growth is a main force for momentum investors.
- Strong Sales Increase: Revenue growth is also very high, with the last quarter up 81.5% year-over-year. The quarters before showed even higher growth rates of 121.7% and 164.1%, showing the company's commercial products, like its lead drug ZORYVE, are getting good market hold.
- Steady Performance: Arcutis has shown a skill to beat hopes, topping both EPS and revenue guesses in each of the last four quarters. The average EPS beat is a notable 49.3%, showing that analyst models are regularly behind the company's operational performance.
- Getting Better Profitability: The company's profit margin in the last reported quarter was 13.4%, a good increase from 7.5% in the quarter before. This move toward profitability is important for keeping growth and is a good sign for the basic health of the business.
These parts together support the high HGM Rating. For momentum investors, the mix of speeding growth, positive beats, and growing margins forms a strong fundamental story that often comes before continued investor interest.
Technical Condition and Setup Quality
While good fundamentals give the "why," technical study helps with the "when." According to the detailed ChartMill Technical Report, Arcutis gets a 7 for both its Technical Rating and its Setup Quality Rating, showing a good match of trend and timing.
- Good Technical Base: The overall technical rating of 7 puts ARQT in an upward trend. The report notes a positive long-term trend, and the stock has done better than 86% of the market over the past year. It is now trading in the upper half of its one-month range, showing relative force even as the wider S&P 500 shows a neutral short-term trend.
- Clear Coming Together Pattern: The Setup Rating of 7 is especially notable for traders. The study points to "reduced movement while prices have been coming together in the newest period." This forming of a tighter trading range after a rise is a common setup that often comes before a new price move.
- Clear Risk and Reward Measures: The technical report finds a main resistance area between $24.19 and $24.82. A clear move above this area could show the start of a new step higher. On the other hand, well-marked support levels are noted near $21.66 and $21.22, giving logical areas for stop-loss placement. This creates an organized situation where the possible gain (a move upward) is measured against a set risk (the support level).
A Coming Together Chance
Arcutis Biotherapeutics presents a case where fundamental momentum and technical position agree. The company's very high growth numbers and steady performance support the high-growth investment idea. At the same time, the stock's price action has formed a coming together pattern with clear technical levels, giving a possible entry point for investors who prefer not to follow extended moves.
This agreement is exactly what the screening method tries to find: companies with the fundamental engine to push future results that are also technically set for a nearer-term move up. It connects the space between a strong long-term story and a tactical shorter-term chance.
Find More Possible Setups The screen that found Arcutis is made to find similar chances where high growth momentum meets good technical setups. You can look at the current results and run this screen yourself by going to the High Growth Momentum Breakout Setups page.
Disclaimer: This article is for information only and does not make investment advice, a suggestion, or an offer to buy or sell any security. The study is based on given data and should not be the only base for any investment choice. Investing has risk, including the possible loss of the main amount. Always do your own study and think about talking with a qualified financial advisor before making any investment choices.